Based on our findings that ketone bodies mediated a decrease in the expression of GLUT1 resulting in a metabolic flux, we evaluated if inhibiting the glycolytic flux alters the cachectic potential in cancer cells. The gene discussed is SLC2A1; the disease is cancer.